ABSTRACT
Trichoepitheliomas are benign skin tumors with follicular differentiation that present most commonly as solitary lesions. They can also present as multiple centrofacial papules due to several mutations in the CYLD gene. Multiple unilateral trichoepitheliomas in a linear or dermatomal distribution may rarely be seen. Herein, we report a case of multiple unilateral trichoepitheliomas on the face of a healthy 34-year-old woman of Caucasian origin.
Subject(s)
Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/microbiology , Skin Neoplasms/genetics , Skin Neoplasms/microbiology , Borrelia burgdorferi , Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 18/genetics , Humans , Lyme Disease/complications , Translocation, Genetic/geneticsSubject(s)
Neurosyphilis/diagnosis , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Female , Greece/epidemiology , Humans , Incidence , Male , Middle Aged , Neurosyphilis/drug therapy , Neurosyphilis/epidemiology , Penicillin G Benzathine/therapeutic use , Treatment OutcomeSubject(s)
Facial Dermatoses/parasitology , Mite Infestations/diagnosis , Skin Diseases, Parasitic/diagnosis , Aged , Anti-Infective Agents/therapeutic use , Combined Modality Therapy , Facial Dermatoses/therapy , Humans , Hydroxyurea/adverse effects , Low-Level Light Therapy , Male , Metronidazole/therapeutic use , Mite Infestations/therapy , Skin Diseases, Parasitic/therapySubject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Clarithromycin/pharmacology , Foot Ulcer/drug therapy , Ofloxacin/pharmacology , Pseudomonas aeruginosa , Aged , Anti-Bacterial Agents/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination , Foot Ulcer/etiology , Foot Ulcer/microbiology , Foot Ulcer/pathology , Humans , Male , Ofloxacin/therapeutic use , Radiotherapy/adverse effects , Sarcoma, Kaposi/radiotherapy , Skin/microbiology , Skin/pathology , Wound Healing/drug effectsSubject(s)
Helicobacter Infections/complications , Helicobacter pylori , Lymphoma, B-Cell, Marginal Zone/complications , Skin Neoplasms/complications , Adult , Amoxicillin/administration & dosage , Clarithromycin/administration & dosage , Diagnosis, Differential , Drug Therapy, Combination , Female , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Humans , Lymphoma, B-Cell, Marginal Zone/diagnosis , Lymphoma, B-Cell, Marginal Zone/drug therapy , Male , Middle Aged , Omeprazole/administration & dosage , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapyABSTRACT
Bowen's disease (BD) is a squamous cell carcinoma in situ. Recent studies suggest that human papilloma virus plays an important role in the development of BD. We investigated whether imiquimod 5%, a topical immune response modifier, is an effective treatment for BD in five immunocompetent patients. The lesions were one genital and four extragenital. The frequency of application varied from three times weekly up to twice daily, and treatment duration ranged from 8-24 weeks. Four patients achieved clinical and histological cure. The patient with the genital lesion gained an important reduction in size and infiltration, which enabled surgical removal of the remaining lesion with good functional and cosmetic result. Our results suggest that topical imiquimod 5% is an effective treatment for BD through its viral and antitumor effects.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Aminoquinolines/therapeutic use , Antiviral Agents/therapeutic use , Bowen's Disease/drug therapy , Carcinoma, Squamous Cell/drug therapy , Skin Neoplasms/drug therapy , Administration, Topical , Aged , Antineoplastic Agents/pharmacology , Biopsy , Epidermis/pathology , Female , Humans , Imiquimod , Male , Middle Aged , Papillomaviridae/metabolism , Papillomavirus Infections/drug therapy , Time Factors , Treatment OutcomeABSTRACT
In severe papulopustular and in nodulocystic/conglobate acne, oral isotretinoin is the treatment of choice. It is also required for patients with moderate to severe acne, especially when acne scars start to occur A new therapeutic approach consists of a low-dose regimen of isotretinoin. We performed a comparative study of high- and low-dose schemas of isotretinoin per os for the treatment of acne. The purpose of this study was to assess the therapeutic effect and tolerability of low doses of isotretinoin in the treatment of acne vulgaris and compare low-dose with high-dose regimens. Sixty-four patients (35 women and 29 men) with different types and grades of acne vulgaris were divided into two treatment groups of 32 patients, in a trial that compared a low dose of 0.15-0.40 mg/kg per day with a high dose of 0.5-1.0 mg/kg per day. These regimens were analyzed with reference to clinical history of acne, baseline investigations, dose and response to isotretinoin, clinical and laboratory adverse effects, relapses and cost of therapy. The mean success rate of the low-dose schema was 69%. The total dose up to 120 mg/kg should be followed for optimal results (success rate of 91%) and avoidance of relapses. The low-dose schema produced fewer adverse effects and offered a very beneficial effect on pre-existing scarring. Our results confirm the beneficial effect of the low-dose schema. We recommend a total dose > or = 120 mg/kg, as this therapeutic regimen of isotretinoin has proven to be the most successful in preventing relapses and scarring.
